Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024 - Seite 3

 

Update on Revenue Generating Products

 

• Historically, Nicox has been generating and reporting royalty revenues from the sales of its products by its partners, primarily Bausch + Lomb for the commercialization of VYZULTA, and from upfront and milestone payments from its licensing agreements. We expect to add to this the royalty revenue from Ocumension from the commercialization of ZERVIATE in China this year and, in the future, from the commercialization of NCX 470 by Ocumension and Kowa, by its future partners in the U.S. and potentially other territories. Nicox estimates annual global net sales of NCX 470 could be over $300 million¹ within 8 years of the date of launches in the U.S. and China.

• VYZULTA – Nicox continues to receive royalties on net sales of VYZULTA. Bausch + Lomb, exclusive worldwide partner of Nicox, reported 35% revenue growth for VYZULTA in 2023. VYZULTA is commercialized by Bausch + Lomb in more than 15 countries and territories, including the U.S., and is also approved in a number of other countries. VYZULTA is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension.
• ZERVIATE – Our forecasts assume that the majority of the ZERVIATE revenue will come from the sales of ZERVIATE in China by our exclusive Chinese partner Ocumension. ZERVIATE is expected to be approved in China shortly, following submission of the NDA there in April 2023.   Ocumension forecasts peak annual net sales of over $100 million within 7 years of launch in China. ZERVIATE is also currently commercialized in the U.S. for ocular itching associated with allergic conjunctivitis by Harrow, Inc. In January 2024, Nicox expanded the territory of the exclusive licensing agreement with Harrow, Inc., to include Canada. No payment was associated with the extension of the territory, and Nicox would receive royalties on any net sales of ZERVIATE in Canada. ZERVIATE forms part of Harrow’s recent agreement with Apotex for Canada.

 

 

Update on Cash Runway

The Company is financed to at least November 2024, based on focusing exclusively on the development of NCX 470.   The Company is pursuing business development discussions, including the sale or license of certain assets, and exploring multiple strategic options which could further extend the cash runway. The Company is evaluating all options for financing and will use the most appropriate at the time.